Changes in period and cohort effects on haematological cancer mortality in Spain, 1952-2006

BMC Cancer

Roberto Pastor-Barriuso¹  Gonzalo López-Abente¹ 

[1] Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Melchor Fernández Almagro 3-5, 28029, Madrid, Spain

关键词: Diagnosis and certification improvements;    Change-points;    Period and cohort effects;    Haematological cancer mortality;   

Others  :  858907
DOI  :  10.1186/1471-2407-14-250

 received in 2013-11-29, accepted in 2014-03-31,  发布年份 2014

【 摘 要 】

Background

In contrast to other haematological cancers, mortality from non-Hodgkin’s lymphoma and multiple myeloma increased dramatically during the second half of the 20th century in most developed countries. This widespread upward trend remains controversial, as it may be attributable either to progressive improvements in diagnosis and certification or to increasing exposures to little-known but relevant risk factors.

Methods

To assess the relative contribution of these factors, we analysed the independent effects of age, death period, and birth cohort on haematological cancer mortality rates in Spain across the period 1952-2006. Weighted joinpoint regression analyses were performed to detect and estimate changes in period and cohort curvatures.

Results

Although mortality rates were consistently higher among men, trends across periods and cohorts were virtually identical in both sexes. There was an early period trend reversal in the 1960s for Hodgkin’s disease and leukaemia, which was delayed to the 1980s for multiple myeloma and the 1990s for non-Hodgkin’s lymphoma. Birth cohort patterns showed a first downturn for generations born in the 1900s and 1910s for all haematological cancers, and a second trend reversal for more recent cohorts born in the 1950s and 1960s for non-Hodgkin’s lymphoma and leukaemia.

Conclusions

The sustained decline in Hodgkin’s disease mortality and the levelling off in leukaemia seem to be driven by an early period effect linked to improvements in disease treatment, whereas the steep upward trends in non-Hodgkin’s lymphoma and multiple myeloma mortality in Spain are more likely explained by a cohort effect linked to better diagnosis and death certification in the elderly. The consistent male excess mortality across all calendar periods and age groups points to the importance of possible sex-related genetic markers of susceptibility in haematological cancers.

【 授权许可】

   
2014 Pastor-Barriuso and López-Abente; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F: GLOBOCAN 2012, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. Lyon, France: International Agency for Research on Cancer; 2013. [http://globocan.iarc.fr webcite]
• [2]Steliarova-Foucher E, O’Callaghan M, Ferlay J, Masuyer E, Forman D, Comber H, Bray F: European Cancer Observatory: Cancer Incidence, Mortality, Prevalence and Survival in Europe. Lyon, France: European Network of Cancer Registries, International Agency for Research on Cancer; 2012. [http://eco.iarc.fr webcite]
• [3]La Vecchia C, Negri E, Levi F, Decarli A, Boyle P: Cancer mortality in Europe: effects of age, cohort of birth and period of death. Eur J Cancer 1998, 34:118-141.
• [4]Bertuccio P, Bosetti C, Malvezzi M, Levi F, Chatenoud L, Negri E, La Vecchia C: Trends in mortality from leukemia in Europe: an update to 2009 and a projection to 2012. Int J Cancer 2013, 132:427-436.
• [5]Pollán M, López-Abente G, Plá-Mestre R: Time trends in mortality for multiple myeloma in Spain, 1957-1986. Int J Epidemiol 1993, 22:45-50.
• [6]Pollán M, López-Abente G, Moreno C, Vergara A, Aragonés N, Ruiz M, Ardanaz E, Moreo P: Rising incidence of non-Hodgkin’s lymphoma in Spain: analysis of period of diagnosis and cohort effects. Cancer Epidemiol Biomarkers Prev 1998, 7:621-625.
• [7]Cartwright R, Brincker H, Carli PM, Clayden D, Coebergh JW, Jack A, McNally R, Morgan G, de Sanjose S, Tumino R, Vornanen M: The rise in incidence of lymphomas in Europe 1985-1992. Eur J Cancer 1999, 35:627-633.
• [8]Groves FD, Linet MS, Travis LB, Devesa SS: Cancer surveillance series: non-Hodgkin’s lymphoma incidence by histologic subtype in the United States from 1978 through 1995. J Natl Cancer Inst 2000, 92:1240-1251.
• [9]Liu S, Semenciw R, Mao Y: Increasing incidence of non-Hodgkin’s lymphoma in Canada, 1970-1996: age-period-cohort analysis. Hematol Oncol 2003, 21:57-66.
• [10]Clarke CA, Glaser SL: Changing incidence of non-Hodgkin lymphomas in the United States. Cancer 2002, 94:2015-2023.
• [11]Sandin S, Hjalgrim H, Glimelius B, Rostgaard K, Pukkala E, Askling J: Incidence of non-Hodgkin’s lymphoma in Sweden, Denmark, and Finland from 1960 through 2003: an epidemic that was. Cancer Epidemiol Biomarkers Prev 2006, 15:1295-1300.
• [12]Bosetti C, Bertuccio P, Levi F, Lucchini F, Negri E, La Vecchia C: Cancer mortality in the European Union, 1970-2003, with a joinpoint analysis. Ann Oncol 2008, 19:631-640.
• [13]Marcos-Gragera R, Pollán M, Chirlaque MD, Gumà J, Sanchez MJ, Garau I: Attenuation of the epidemic increase in non-Hodgkin’s lymphomas in Spain. Ann Oncol 2010, 21(Suppl 3):iii90-iii96.
• [14]Storm HH, Klint A, Tryggvadóttir L, Gislum M, Engholm G, Bray F, Hakulinen T: Trends in the survival of patients diagnosed with malignant neoplasms of lymphoid, haematopoietic, and related tissue in the Nordic countries 1964-2003 followed up to the end of 2006. Acta Oncol 2010, 49:694-712.
• [15]Holford TR: Understanding the effects of age, period, and cohort on incidence and mortality rates. Annu Rev Public Health 1991, 12:425-457.
• [16]Spanish National Institute of Statistics http://www.ine.es/en/inebmenu/indice_en.htm webcite
• [17]Pérez-Gómez B, Aragonés N, Pollán M, Suárez B, Lope V, Llácer A, López-Abente G: Accuracy of cancer death certificates in Spain: a summary of available information. Gac Sanit 2006, 20(Suppl 3):42-51.
• [18]McCullagh P, Nelder JA: Generalized Linear Models. 2nd edition. London, UK: Chapman & Hall; 1989.
• [19]Holford TR: The estimation of age, period and cohort effects for vital rates. Biometrics 1983, 39:311-324.
• [20]Carstensen B: Age-period-cohort models for the Lexis diagram. Stat Med 2007, 26:3018-3045.
• [21]Kim HJ, Fay MP, Feuer EJ, Midthune DN: Permutation tests for joinpoint regression with applications to cancer rates. Stat Med 2000, 19:335-351.
• [22]Kupper LL, Janis JM, Karmous A, Greenberg BG: Statistical age-period-cohort analysis: a review and critique. J Chronic Dis 1985, 38:811-830.
• [23]Armitage JO, Bierman PJ, Bociek RG, Vose JM: Lymphoma 2006: classification and treatment. Oncology 2006, 20:231-239.
• [24]Fisher SG, Fisher RI: The epidemiology of non-Hodgkin’s lymphoma. Oncogene 2004, 23:6524-6534.
• [25]Bassig BA, Lan Q, Rothman N, Zhang Y, Zheng T: Current understanding of lifestyle and environmental factors and risk of non-hodgkin lymphoma: an epidemiological update. J Cancer Epidemiol 2012, 2012:978930.
• [26]Viel JF, Fournier E, Danzon A: Age-period-cohort modelling of non-Hodgkin’s lymphoma incidence in a French region: a period effect compatible with an environmental exposure. Environ Health 2010, 9:47. BioMed Central Full Text
• [27]Levi F, Lucchini F, Negri E, Boyle P, La Vecchia C: Trends in mortality from Hodgkin’s disease in western and eastern Europe. Br J Cancer 2002, 87:291-293.
• [28]Gustavsson A, Osterman B, Cavallin-Ståhl E: A systematic overview of radiation therapy effects in Hodgkin’s lymphoma. Acta Oncol 2003, 42:589-604.
• [29]Levi F, Lucchini F, Negri E, Barbui T, La Vecchia C: Trends in mortality from leukemia in subsequent age groups. Leukemia 2000, 14:1980-1985.
• [30]Edgren G, Liang L, Adami HO, Chang ET: Enigmatic sex disparities in cancer incidence. Eur J Epidemiol 2012, 27:187-196.
• [31]Van Vlierberghe P, Palomero T, Khiabanian H, Van der Meulen J, Castillo M, Van Roy N, De Moerloose B, Philippé J, González-García S, Toribio ML, Taghon T, Zuurbier L, Cauwelier B, Harrison CJ, Schwab C, Pisecker M, Strehl S, Langerak AW, Gecz J, Sonneveld E, Pieters R, Paietta E, Rowe JM, Wiernik PH, Benoit Y, Soulier J, Poppe B, Yao X, Cordon-Cardo C, Meijerink J, et al.: PHF6 mutations in T-cell acute lymphoblastic leukemia. Nat Genet 2010, 42:338-342.
• [32]Van Vlierberghe P, Patel J, Abdel-Wahab O, Lobry C, Hedvat CV, Balbin M, Nicolas C, Payer AR, Fernandez HF, Tallman MS, Paietta E, Melnick A, Vandenberghe P, Speleman F, Aifantis I, Cools J, Levine R, Ferrando A: PHF6 mutations in adult acute myeloid leukemia. Leukemia 2011, 25:130-134.
• [33]Yoo NJ, Kim YR, Lee SH: Somatic mutation of PHF6 gene in T-cell acute lymphoblastic leukemia, acute myelogenous leukemia and hepatocellular carcinoma. Acta Oncol 2012, 51:107-111.
• [34]Navarro C, Martos C, Ardanaz E, Galceran J, Izarzugaza I, Peris-Bonet R, Martínez C: Population-based cancer registries in Spain and their role in cancer control. Ann Oncol 2010, 21(Suppl 3):iii3-iii13.
• [35]Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML, Delsol G, De Wolf-Peeters C, Falini B, Gatter KC: A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994, 84:1361-1392.